These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 35530750)

  • 1. Recent Progress in Systemic Therapy for Hepatocellular Cancer (HCC).
    Ghaziani TT; Dhanasekaran R
    Curr Treat Options Gastroenterol; 2021 Jun; 19(2):351-368. PubMed ID: 35530750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-Line Targeted Therapy for Hepatocellular Carcinoma: Role of Atezolizumab/Bevacizumab Combination.
    Tella SH; Kommalapati A; Mahipal A; Jin Z
    Biomedicines; 2022 Jun; 10(6):. PubMed ID: 35740326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of immunotherapy in the management of hepatocellular carcinoma: current standards and future directions.
    Weinmann A; Galle PR
    Curr Oncol; 2020 Nov; 27(Suppl 3):S152-S164. PubMed ID: 33343209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic targeted and immunotherapy for advanced hepatocellular carcinoma.
    Cersosimo RJ
    Am J Health Syst Pharm; 2021 Jan; 78(3):187-202. PubMed ID: 33211092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent Advances in Systemic Therapy for Hepatocellular Carcinoma in an Aging Society: 2020 Update.
    Kudo M
    Liver Cancer; 2020 Dec; 9(6):640-662. PubMed ID: 33442538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook.
    Fan Y; Xue H; Zheng H
    J Hepatocell Carcinoma; 2022; 9():233-263. PubMed ID: 35388357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapies for hepatocellular carcinoma.
    Llovet JM; Castet F; Heikenwalder M; Maini MK; Mazzaferro V; Pinato DJ; Pikarsky E; Zhu AX; Finn RS
    Nat Rev Clin Oncol; 2022 Mar; 19(3):151-172. PubMed ID: 34764464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic therapy for advanced hepatocellular carcinoma: targeted therapies.
    Tella SH; Kommalapati A; Mahipal A
    Chin Clin Oncol; 2021 Feb; 10(1):10. PubMed ID: 32434345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy in Advanced Hepatocellular Carcinoma.
    Javan H; Dayyani F; Abi-Jaoudeh N
    Semin Intervent Radiol; 2020 Dec; 37(5):466-474. PubMed ID: 33328702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular therapies for HCC: Looking outside the box.
    Faivre S; Rimassa L; Finn RS
    J Hepatol; 2020 Feb; 72(2):342-352. PubMed ID: 31954496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug Treatment for Advanced Hepatocellular Carcinoma: First-Line and Beyond.
    Feng MY; Chan LL; Chan SL
    Curr Oncol; 2022 Aug; 29(8):5489-5507. PubMed ID: 36005172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review.
    Ahmed F; Onwumeh-Okwundu J; Yukselen Z; Endaya Coronel MK; Zaidi M; Guntipalli P; Garimella V; Gudapati S; Mezidor MD; Andrews K; Mouchli M; Shahini E
    World J Gastrointest Oncol; 2021 Nov; 13(11):1813-1832. PubMed ID: 34853653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Critical Appraisal of Guideline Recommendations on Systemic Therapies for Advanced Hepatocellular Carcinoma: A Review.
    Cappuyns S; Corbett V; Yarchoan M; Finn RS; Llovet JM
    JAMA Oncol; 2024 Mar; 10(3):395-404. PubMed ID: 37535375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paradigm shift in the treatment options of hepatocellular carcinoma.
    Su TH; Hsu SJ; Kao JH
    Liver Int; 2022 Aug; 42(9):2067-2079. PubMed ID: 34515412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy and chimeric antigen receptor T-cell therapy in hepatocellular carcinoma.
    Uson Junior PLS; Liu AJ; Sonbol MB; Borad MJ; Bekaii-Saab TS
    Chin Clin Oncol; 2021 Feb; 10(1):11. PubMed ID: 33541088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current treatment options for hepatocellular carcinoma.
    Eugen K
    Klin Onkol; 2020; 33(Supplementum 3):20-25. PubMed ID: 33213161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in therapeutic options for hepatocellular carcinoma in Asia.
    Ogasawara S; Koroki K; Kanzaki H; Kobayashi K; Kiyono S; Nakamura M; Kanogawa N; Saito T; Kondo T; Nakagawa R; Nakamoto S; Muroyama R; Chiba T; Kato N
    Liver Int; 2022 Aug; 42(9):2055-2066. PubMed ID: 34780081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New systemic agents for hepatocellular carcinoma: an update 2020.
    von Felden J
    Curr Opin Gastroenterol; 2020 May; 36(3):177-183. PubMed ID: 32101985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HCC and Molecular Targeting Therapies: Back to the Future.
    Rinaldi L; Vetrano E; Rinaldi B; Galiero R; Caturano A; Salvatore T; Sasso FC
    Biomedicines; 2021 Sep; 9(10):. PubMed ID: 34680462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging drugs for the treatment of hepatocellular carcinoma.
    Ayoub WS; Jones PD; Yang JD; Martin P
    Expert Opin Emerg Drugs; 2022 Jun; 27(2):141-149. PubMed ID: 35642526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.